ÁøÇ༺ À¯¹æ¾Ï ȯÀÚ¿¡¼ ½Åº¸° ÈÇпä¹ý ÈÄ Á¾¾çÀÇ ¹ÝÀÀ¼º Æò°¡: ÀÚ±â°ø¸í¿µ»ó°ú ¾çÀüÀÚ´ÜÃþÃÔ¿µÀÇ ºñ±³(RECIST 1.1°ú PERCIST 1.0)
Response Evaluation to Neoadjuvant Chemotherapy in Advanced Breast Cancer: Comparison of MRI and Positron Emission Tomography/CT (RECIST 1.1 versus PERCIST 1.0)
´ëÇÑ¿µ»óÀÇÇÐȸÁö 2014³â 71±Ç 2È£ p.89 ~ p.96
¾È¿µÀÌ(An Yeong-Yi) - Catholic University College of Medicine St. Vincent¡¯s Hospital Department of Radiology
±è¼ºÇå(Kim Sung-Hun) - Catholic University College of Medicine Seoul St. Mary¡¯s Hospital Department of Radiology
¹Ú¿µÇÏ(Park Young-Ha) - Catholic University College of Medicine St. Vincent¡¯s Hospital Department of Radiology
Abstract
Purpose: The aim of this study was to compare the diagnostic performances between the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) criteria on dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) and positron emission tomography Response Evaluation Criteria in Solid Tumors version 1.0 (PERCIST 1.0) criteria on positron emission tomography/CT (PET/CT) in evaluating the treatment response of neoadjuvant chemotherapy (NAC) in breast cancer patients.
Materials and Methods: We compared MRI and PET/CT in the assessment of tumor response after NAC with the pathological response as the standard reference in 54 breast cancer patients. The tumor response was assessed by using the RECIST 1.1 criteria on DCE-MRI and PERCIST 1.0 criteria on PET/CT. The diagnostic performance of RECIST 1.1 and PERCIST 1.0 criteria was statistically analyzed and compared by receiver operating characteristic (ROC) analysis.
Results: There were 21 responders and 33 non-responders according to the pathology. The discordant rate with pathological response was 37.0% for RECIST 1.1 and 55.6% for PERCIST 1.0. Twenty six patients (48.1%) were classified as responders in both MRI and PET/CT, but the final pathology showed non-response. In the ROC curve, the area under the curves (AUC) was 0.89 for RECIST 1.1 and 0.79 for PERCIST 1.0 (p < 0.001).
Conclusion: The RECIST 1.1 criteria on MRI showed the better diagnostic performance than PERCIST 1.0 criteria on PET/CT for the response assessment of breast cancer after NAC, although there was no statistically significant difference between both (p = 0.15).
Å°¿öµå
Breast Cancer, Neoadjuvant Chemotherapy, Magnetic Resonance Imaging, Positron Emission Tomography
KMID :
1103720140710020089
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)